Sofía Braga

Subsequent Treatments After Progression on Cyclin-Dependent Kinase 4/6 Inhibitors: A Review of the Evidence and a Real-World Data Perspective From Portuguese Hospitals

Rita Freitas, Tiago Barroso, Sofía Braga, Catarina C Santos et autres

BACKGROUND: The treatment with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) (ribociclib, palbociclib, and abemaciclib) combined with endocrine therapy (ET) has become the standard of care (SoC) for first-line treatment in patients with metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative …

pt, br, us (code pays fourni par la source)

18F-FDG-PET-guided, pathological complete response-adapted chemotherapy de-escalation in HER2-positive early breast cancer: 5-year outcomes and exploratory ctDNA analyses from the randomized phase 2 PHERGain trial

Antonio Llombart‐Cussac, José Manuel Pérez-García, Javier Cortés, Manuel Ruiz-Borrego et autres

es, ch, fr, gb, be, de, it, pt, us (code pays fourni par la source)

531P Ribociclib treatment patterns and clinical outcomes among women with HR+/HER2- advanced or metastatic breast cancer in Portugal: Final 3-year results from breast cancer lighthouse real-world study

L.I. Pinto, A.L.V. Matos, Belén Pequeño, A.M. Nogal Dias et autres

pt, us, fr (code pays fourni par la source)

Brain imaging screening in metastatic breast cancer: patients’ and physicians’ perspectives

Leonor Vasconcelos de Matos, Mette van Ramshorst, Volkmar Müller, Elisa Agostinetto et autres

BACKGROUND: Routine brain imaging screening (BIS) in patients with metastatic breast cancer (BC) without neurological symptoms is currently not recommended, as no survival/quality-of-life improvements have been demonstrated. We aimed to examine physicians and patients' attitudes and perceptions toward BIS. METHODS: International cross-sectional …

pt, nl, de, be, it, fr, ca, se, es (code pays fourni par la source)

Abstract P5-01-12: Subsequent Treatments After Progression On Cyclin-Dependent Kinase 4/6 Inhibitors - A Multicentric Portuguese Real-world Data Study

A.R. Freitas, Inês Eiriz, Marta Vaz Batista, Andreia Chaves et autres

Abstract Background: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) (Ribociclib, Palbociclib or Abemaciclib) plus endocrine therapy (ET) is the standard first line treatment in hormone receptor-positive (HR+) human epidermal growth factor receptor two-negative (HER2-) metastatic breast cancer (MBC) patients (pts). There are no established …

ALISertib in combination with endocrine therapy in patients with hormone receptor-positive (HR+), HER2-negative (HER2–) recurrent or metastatic breast cancer: The phase 2 ALISCA-Breast1 study.

Pooja Advani, Sofía Braga, Adam Brufsky, Karthik V. Giridhar et autres

TPS1125 Background: Despite the many available treatments for patients (pts) with HR+, HER2– recurrent/metastatic breast cancer (MBC), optimal treatment after progression on CDK4/6 inhibitors (CDK4/6i) is unclear. One possible CDK4/6i resistance mechanism is increased expression of Aurora kinase A (AURKA), a key …

us, es (code pays fourni par la source)

315P Real-world safety and effectiveness of T-DXd in older advanced breast cancer Patients: Updated analysis in an expanded cohort from the TREX-old registry

Antoine Deleuze, Simone Nardin, Eva Valentina Klocker, Anca Chelariu-Raicu et autres

One-third of advanced breast cancer (ABC) patients are over 70, yet this group is underrepresented in trials. T-DXd has demonstrated effectiveness in HER2-low and HER2+ ABC with a manageable safety profile. However, interstitial lung disease (ILD) is reported in 10–15% of patients, …

fr, at, de, es, it, pt (code pays fourni par la source)

105P Subsequent treatments after progression on cyclin-dependent kinase 4/6 inhibitors: A multicentric real-world data study

André Ricardo Ribas Freitas, Inês Eiriz, Marta Vaz Batista, Carla S. Santos et autres

pt (code pays fourni par la source)

The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis

Marta Vaz Batista, José Manuel Pérez-García, Laia Garrigós, José Á. García-Sáenz et autres

pt, es (code pays fourni par la source)

Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial

Marta Vaz Batista, José Manuel Pérez-García, Patricia Cortez, Laia Garrigós et autres

BACKGROUND: Trastuzumab deruxtecan (T-DXd) is approved for human epidermal growth factor receptor 2 (HER2)-positive and HER2-low advanced breast cancer (ABC). T-DXd has shown encouraging intracranial activity in HER2-positive ABC patients with stable or active brain metastases (BMs); however, its efficacy in patients …

pt, es (code pays fourni par la source)

410P Breast cancer lighthouse non-interventional hybrid real-world study: Molecular characterization and 2-year effectiveness data

A.M. Nogal Dias, A.L.V. Matos, B.E. Gosalbez Pequeno, Sofía Braga et autres

pt, fr (code pays fourni par la source)

OCTS-03 A MULTICENTER, OPEN-LABEL, SINGLE-ARM, MULTICOHORT PHASE II CLINICAL TRIAL OF TRASTUZUMAB DERUXTECAN IN HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-POSITIVE AND HER2-LOW ADVANCED BREAST CANCER (ABC) WITH BRAIN METASTASES AND/OR LEPTOMENINGEAL CARCINOMATOSIS (LMC) – THE DEBBRAH STUDY

Marta Vaz-Batista, José Manuel Pérez-García, Patricia Cortez, Laia Garrigós et autres

Abstract The DEBBRAH study (NCT04420598) evaluated the efficacy and safety of trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate, in patients with HER2-positive and HER2-low ABC with brain metastases (BM) and/or LMC. Forty-one patients aged ≥18 years were enrolled in 5 cohorts: (1) HER2-positive …

pt, es (code pays fourni par la source)